• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ERCC1 Gene Record

  • Summary
  • Interactions
  • Claims
  • ERCC1 2067 Clinically Actionable

    Alternate Names:

    2067
    ERCC EXCISION REPAIR 1, ENDONUCLEASE NON-CATALYTIC SUBUNIT
    ERCC1
    COFS4
    RAD10
    UV20
    126380
    3433
    ENSG00000012061
    OTTHUMG00000182121
    PA155
    1735

    Gene Info:

    Gene Biotype PROTEIN_CODING
    (3 More Sources)

    Gene Categories: Category Details

    DNA REPAIR
    CLINICALLY ACTIONABLE

    Publications:

    Bellmunt J et al., 2007, Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy., Ann Oncol
    Ceppi P et al., 2006, ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine., Ann Oncol
    Yokoi M et al., 2018, Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy., Support Care Cancer
    Li et al., 1998, Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells., Int. J. Oncol.
    Li et al., Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line., Anticancer Res.
    Goldberg et al., 2001, An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin., Int. J. Radiat. Oncol. Biol. Phys.
    Li et al., Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells., Anticancer Res.
    Pérez-Ramírez C et al., 2019, Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients., Pharmacogenomics J
    Pérez-Ramírez C et al., 2016, Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients., Pharmacol Res
    Sullivan I et al., 2014, Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy., Cancer Lett
    Rumiato E et al., 2013, ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy., Pharmacogenet Genomics
    Yan L et al., 2012, Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy., Pharmacogenomics
    Khrunin A et al., 2012, Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins., Pharmacogenomics
    Giovannetti E et al., 2011, Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy., Pharmacogenomics
    Tzvetkov MV et al., 2011, Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms., Pharmacogenomics
    Zucali PA et al., 2011, Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin., Clin Cancer Res
    Huang MY et al., 2011, Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy., Pharmacogenet Genomics
    Khrunin AV et al., 2010, Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients., Pharmacogenomics J
    Kalikaki A et al., 2009, DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer., Clin Lung Cancer
    Kim HS et al., 2009, Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study., Gynecol Oncol
    Tibaldi C et al., 2008, Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients., Clin Cancer Res
    Kawashima et al., 2011, Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer., Clin. Cancer Res.
    Usanova et al., 2010, Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression., Mol. Cancer
    Postel-Vinay et al., 2013, A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer., Oncogene
    Cheng et al., 2013, PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells., Carcinogenesis
    Rosell et al., 2006, Pharmacogenomics and gemcitabine., Ann. Oncol.
    Cibeira MT et al., 2011, Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide., Leuk Res
    Bosó V et al., 2014, SNPs and taxane toxicity in breast cancer patients., Pharmacogenomics
    Lee KH et al., 2013, Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer., Cancer Chemother Pharmacol
    Cheng L et al., 2017, Functional genetic variants of XRCC4 and ERCC1 predict survival of gastric cancer patients treated with chemotherapy by regulating the gene expression., Mol Carcinog
    Fujishima et al., 1997, Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line., Oncol. Res.
    Sebio A et al., 2015, EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer., Pharmacogenomics J
  • PLATINUM   ERCC1

    Interaction Score: 3.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29662106 27498158 25069034 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182


    Sources:
    PharmGKB

  • PALONOSETRON   ERCC1

    Interaction Score: 2.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29177570


    Sources:
    PharmGKB

  • OXALIPLATIN   ERCC1

    Interaction Score: 1.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29662106 27498158 25069034 23314736 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182


    Sources:
    PharmGKB

  • CISPLATIN   ERCC1

    Interaction Score: 0.7

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9772291 9703867 11163512 10810335 29662106 27498158 25069034 23962907 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 19203783 18347182 21177407 20846399 23934192 23275151 17229776 16980606 16807441


    Sources:
    NCI CIViC PharmGKB

  • CARBOPLATIN   ERCC1

    Interaction Score: 0.6

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29662106 27498158 25069034 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182


    Sources:
    PharmGKB

  • GRANISETRON   ERCC1

    Interaction Score: 0.56

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29177570


    Sources:
    PharmGKB

  • LEUCOVORIN   ERCC1

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23314736 21057378


    Sources:
    PharmGKB

  • FLUOROURACIL   ERCC1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28796378 23314736 21057378 9268987


    Sources:
    NCI PharmGKB

  • THALIDOMIDE   ERCC1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21435719


    Sources:
    PharmGKB

  • CAPECITABINE   ERCC1

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25026457


    Sources:
    PharmGKB

  • BLEOMYCIN   ERCC1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • GEMCITABINE   ERCC1

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17229776 16980606


    Sources:
    CIViC PharmGKB

  • PACLITAXEL   ERCC1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25495407 17229776


    Sources:
    CIViC PharmGKB

  • CYCLOPHOSPHAMIDE   ERCC1

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22188361 19786980


    Sources:
    PharmGKB

  • DOCETAXEL   ERCC1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25495407


    Sources:
    PharmGKB

  • ETOPOSIDE   ERCC1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DOXORUBICIN   ERCC1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • Ensembl: ENSG00000012061

    • Version: 101_38

    Alternate Names:
    ERCC1 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • PharmGKB: ERCC1

    • Version: 18-August-2020

    Alternate Names:
    PA155 PharmGKB ID

    Gene Info:

    Publications:
    Huang MY et al., 2011, Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy., Pharmacogenet Genomics
    Lee KH et al., 2013, Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer., Cancer Chemother Pharmacol
    Sebio A et al., 2015, EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer., Pharmacogenomics J

  • CIViC: ERCC1

    • Version: 14-September-2020

    Alternate Names:
    2067 Entrez Gene ID
    1735 CIViC Gene ID

    Gene Info:

    Publications:
    Ceppi P et al., 2006, ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine., Ann Oncol
    Bellmunt J et al., 2007, Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy., Ann Oncol
    Rosell et al., 2006, Pharmacogenomics and gemcitabine., Ann. Oncol.

  • NCI: ERCC1

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Goldberg et al., 2001, An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin., Int. J. Radiat. Oncol. Biol. Phys.
    Li et al., 1998, Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells., Int. J. Oncol.
    Li et al., Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells., Anticancer Res.

  • Tempus: ERCC1

    • Version: 11-November-2018

    Alternate Names:
    ERCC1 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: ERCC1

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • GO: ERCC1

    • Version: 01-February-2022

    Alternate Names:

    Gene Info:

    Gene Categories:
    DNA REPAIR

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21